Our key offerings include:
These products are available for you to use in your laboratories now…
LightOx probes represent a unique method for the delivery of fluorescent probes into cells. From simple staining, to targeted delivery, the unique properties of Lightox probes enables a multitude of cell staining capabilities
The small size of our probes means they bypass the traditional problems associated with fluorescent probes, providing facile delivery into the cell and minimal disruption to cell activity. Importantly, with powerful fluorescent properties, cellular activity is easy to study through imaging techniques.
LightOx are at the forefront of retinoid research with a patented library of novel highly-potent small molecules with both genomic and non-genomic effects (“Dual-Activity Retinoids”) in neurodegenerative diseases. Retinoids are vitamin A-derived substances that play a crucial role in embryogenesis, development, programmed cell death and other cellular functions.
We are in the process of developing assays and models for neurodegenerative disease states including motor neurone and Alzheimer’s diseases and are looking for partners.
Light-based photo-therapies have been used for a number of years with limited success. Lightox’s new technologies fundamentally change the way in which these therapies can be delivered to the patient.
We can target the therapeutic action to particular body sites, using a simple delivery systems, enabling instant treatment and cell death of selected cells and tissues. Versatile delivery methods make a full range of photo-therapy applications possible.
Collaborative research from Durham, Oxford and York Universities looking at the incorporation of vitamin-A like tags has resulted in the discovery of a new class of compound that is able to penetrate the cell and disrupt cell function causing cell death.
LightOx Ltd have been successful in securing non-diluting grants to further the product portfolio and investigate both new market possibilities and new product developments.
Angel investment has been secured to cover the initial commercialisation and rollout of the existing product range, with further funds being sought to accelerate this process over the coming 24 months.
Dr Whitehouse is an experienced board member with executive experience in both innovation and service based companies. Overseeing the development and commercialisation of world leading products for healthcare products and working with some of the world’s leading institutes, he has brought some of the very best innovations to market. As CEO and board member, he oversees the governance and strategy of the company, giving guidance and structure for the team.
With a background in chemistry and molecular biology, and experienced in bringing research to commercial realisation Dr Whitehouse will oversee product portfolio expansion, regulation and accreditation in our specified target markets, as well as securing the required funding and commercial deals.
Dr Ambler is an Associate Professor in Biosciences at Durham University. She is highly accomplished in the areas using microscopic imaging in 2D and 3D human skin models to study tissue repair and regeneration.
She has numerous publications in international journals and has lectured in several national and international conferences. Her role in the company will be to act as director, as well as direct research and development activities.
Prof Whiting is a Professor in Organic Chemistry at Durham University and has published over 200 peer reviewed papers, patents and reviews. He is expert on organic synthesis, methodology development, organic chemical design and synthesis and has devised fluorescent compounds as part of a project on developing synthetic retinoids as biological probes and for controlling cellular development.
He has published widely in international journals in the organic synthesis field and at its biology interface, and has worked jointly with the CEO for several years in this area. His role will be to direct the design, development and scale up of suitable chemical entities for use as Photokillers, working with the rest of the team to deliver products to market.
Prof Coles is Professor of Immunology at Oxford (publishing over 60 papers), and has been working in cellular and molecular immunology for 20 years. His group utilizes interdisciplinary approaches to understand the development and function of immune environments focusing on the role of stromal cell and immune cell interactions. He has key expertise in imaging (from single molecule to whole tissue imaging), experimental models and systems immunology.
He has developed model driven experimentation as an approach to understand how complex immune – work in health and disease. The Coles group has a strong record working with industry including funding and projects involving GSK, Roche, MedImmune/AstraZeneca and Unilever. He recently spun out SimOmics a company specialized in evidence based modelling and simulation of immune responses.
As chief scientific officer of SimOmics he has helped grow the financial success of the company, undertaking projects to support research and development at pharmaceutical companies. He has previously obtained patent protection for technology to differentiate human mesenchymal stem cells into lymphoid stroma. His role in the company is to support the development of specific cell targeting of the Photokiller-based technologies.
Dr Valentine is CEO at High Force Research Ltd, with over 30 years-experience providing high quality, chemical synthesis and R&D service to the pharmaceutical, agrochemical and fine chemical industries.
His role is to support business development and commercialisation activities.
Mr Paul Lelieveld and Dr Frans van Dalen have joined the LightOx team and will support the development of new light-activated drugs and fluorescent probes being produced at the company. The two appointments bring a wealth of knowledge in the pharmaceutical development and regulatory pathways as well as the investment community in this area.
Further to this LightOx announces that it has successfully closed its current funding round with Dutch Biopharma specialists Meneldor acting as the lead. The investment will help the commercialisation of LightOx Probes for use in research markets, and the development of the new drugs being developed by the team for Head & Neck, and skin cancers.
“We are delighted to welcome Paul and Frans to the team. Their wealth of experience will help us to accelerate our activities in both commercialising our LightOx Probes to a global customer base, and our development of new therapeutics which are activated by light. We look forward to a long and productive future with our new NEDs.”
LightOx Ltd is an openly innovative company and actively partner with a number of companies and institutes across the globe. We strongly encourage our partners to develop and collaborate in a number of application areas and are keen to expand our portfolio with like minded companies and research organisations.
Whether you are a large multinational looking for new avenues, or research based with an interesting idea, we are keen to discuss new directions and applications. Please feel free to get in touch and discuss with us your ideas.
LightOx have developed a number of compounds that are available to licence to help your needs. We are open minded in our approach to broadening these applications areas and so would love to hear from you if you think this can further your business goals.
LightOx has extensive research partners around the globe currently using LightOx probes in their research. We are frequently asked for further developments on the probes and invite collaborative partners to push the limits of the applications currently under investigation.
If you believe these probes may aid your research or you are interested in discussing the potential use of the probes in your own research please contact us.
LightOx is currently seeking new investors who can add value and capital to the operations of the business. We are keen to accelerate the route to market and expand the current product portfolio. Please contact us if you are interested in investment opportunities.
Notch signaling for preparing a population of cells in autologous cell replacement therapy.
Patent Number: WO2012035309-A1.
Synthetic retinoids (in cell killing)
Patent Number: GB1613712.7.
Fluorescent synthetic retinoids.
International Patent WO 2016/055800.